Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2007-08-08

Clinical Trial Update: High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating high-dose isoniazid as adjuvant therapy for multidrug-resistant tuberculosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ISONIAZID (ISONIAZID)

Snippet

Sponsor: GSVM Medical College | Conditions: Tuberculosis, Multidrug-Resistant | Phase 2, Phase 3 | Status: COMPLETED